BioSpace News Archive

Husson University will hold its 2022 Commencement Ceremony on Saturday, May 7, 2022 at the Cross Insurance Center in Bangor, starting at 10:30 a.m. During the ceremony, Husson University will pay special tribute to Saundra Pelletier, the chief executive officer (CEO), president, and executive director of Evofem Biosciences (Nasdaq: EVFM ) of San Diego, California.

Ankyra Therapeutics announced today that the Board of Directors has appointed Howard L. Kaufman, MD as Chief Executive Officer effective March 22, 2022.

Click Therapeutics, Inc. today announced the formation of a Scientific Advisory Board (SAB) comprised of an esteemed group of world-renowned healthcare and technology leaders who will help provide scientific guidance to the company as it expands its therapeutic area reach.

Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “ Company ”) is pleased to announce that, further to the Company’s news release dated February 23, 2022, it has entered into a definitive agreement (the “ Agreement ”) dated March 24, 2022 with Praesidio Health Inc. (“ Praesidio ”). Pursuant to the Agreement, the Company will acquire all of the issued and outstanding shares in the capital of Praesidio.

NLS Pharmaceutics Ltd. announces that it has entered into an agreement with Caligor Coghlan Pharma Services (CCPS) to administer a Named Patient Program enabling European patients with Idiopathic Hypersomnia (IH) to have pre-approval access to treatment with the Company’s novel Mazindol ER formulation.

Dermata Therapeutics, Inc. today highlighted recent corporate progress and reported financial results for the year ended December 31, 2021.

Biobeat, announced today that its wearable remote patient monitoring device have received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to monitor respiratory rate and body temperature in addition to cuffless blood pressure, blood oxygen saturation and pulse rate.

Children’s Hospital of Philadelphia announced that it has received a significant gift from Susan and Steve Kelly, local philanthropists and long-time supporters of CHOP, to establish the Susan S. and Stephen P. Kelly Center for Cancer Immunotherapy.

Clarity Pharmaceuticals, a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that the diagnostic 64Cu SAR-bisPSMA trial for patients with prostate cancer is open for recruitment.

Therapeutic Solutions International announced today its Board of Directors has selected Biorasi as the contract research organization (CRO) to run its Pivotal FDA Registration Clinical Trial assessing efficacy of its JadiCell™ Adult Stem Cell Product in patients with advanced COVID-19.